MERCK KGAA
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 532
- Registration Number
- NCT02252965
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia
- Conditions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 44
- Registration Number
- NCT02208076
- Locations
- 🇨🇴
For Recruiting Locations in Colombia, Please Contact The Merck KGaA Communication Center, Colombia
Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 41
- Registration Number
- NCT02156466
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
c-Met Second-Line Hepatocellular Carcinoma
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 66
- Registration Number
- NCT02115373
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
A Phase 1 TH-302 Mass Balance Trial
- Conditions
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 10
- Registration Number
- NCT02076230
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 200
- Registration Number
- NCT02064816
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 939
- Registration Number
- NCT02047227
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 7
- Registration Number
- NCT02015286
- Locations
- 🇩🇪
For Recruiting Locations in the United Arab Emirates and the Kingdom of Saudi Arabia, Please Contact The Merck KGaA Communication Center, Darmstadt, Germany
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 82
- Registration Number
- NCT02015273
- Locations
- 🇸🇬
KK Women's & Children's Hospital, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
🇮🇩Anakku Clinic Pondok Pinang, Jakarta, Indonesia
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 117
- Registration Number
- NCT01988493
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
🇨🇳Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan